%0 Journal Article %1 Plotkin2006 %A Plotkin, Horacio %A Coughlin, Susan %A Kreikemeier, Rose %A Heldt, Kathryn %A Bruzoni, Matias %A Lerner, Gary %D 2006 %J Dev Med Child Neurol %K Adolescent; Bone Density; Density Conservation Agents; Diseases, Metabolic; Cerebral Palsy; Child; Child, Preschool; Diphosphonates; Disabled Children; Dose-Response Relationship, Drug; Female; Fractures, Bone; Humans; Infusions, Intravenous; Male; Mobility Limitation; Pilot Projects; Severity of Illness Index; Treatment Outcome %N 9 %P 709--712 %R 10.1017/S0012162206001526 %T Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. %U http://dx.doi.org/10.1017/S0012162206001526 %V 48 %X The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP). Twenty-three non-ambulatory children and adolescents (12 females, 11 males; mean age 10y SD 5y, range 4y 1 mo-17 y 11 mo) with severe spastic quadriplegic CP and low BMD were recruited from a multidisciplinary clinic. Severity of CP was graded at Level IV (n=10) and Level V (n=13) using the Gross Motor Function Classification System. Patients received intravenous pamidronate (4.12 mg/kg/y, maximum 45 mg/d) every 4 months. Lumbar spine and femoral neck BMD were measured at baseline and after 4 and 12 months. Twelve months after the first dose of pamidronate there was a significant increase in lumbar spine and femoral neck BMD (p<0.01 for both sites) and z scores compared with baseline values (p<0.01 for both sites). Mean BMD z scores increased 1.6 points for femoral neck and 1.9 points for lumbar spine after 12 months of pamidronate treatment. Serum intact parathyroid hormone increased significantly and cross-linked N-teleopeptide of type I collagen decreased significantly at 12 months. No significant side effect was noted. Low doses of pamidronate are well tolerated and significantly increase BMD in non-ambulatory children and adolescents with CP.

@article{Plotkin2006, abstract = {The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP). Twenty-three non-ambulatory children and adolescents (12 females, 11 males; mean age 10y [SD 5y], range 4y 1 mo-17 y 11 mo) with severe spastic quadriplegic CP and low BMD were recruited from a multidisciplinary clinic. Severity of CP was graded at Level IV (n=10) and Level V (n=13) using the Gross Motor Function Classification System. Patients received intravenous pamidronate (4.12 mg/kg/y, maximum 45 mg/d) every 4 months. Lumbar spine and femoral neck BMD were measured at baseline and after 4 and 12 months. Twelve months after the first dose of pamidronate there was a significant increase in lumbar spine and femoral neck BMD (p<0.01 for both sites) and z scores compared with baseline values (p<0.01 for both sites). Mean BMD z scores increased 1.6 points for femoral neck and 1.9 points for lumbar spine after 12 months of pamidronate treatment. Serum intact parathyroid hormone increased significantly and cross-linked N-teleopeptide of type I collagen decreased significantly at 12 months. No significant side effect was noted. Low doses of pamidronate are well tolerated and significantly increase BMD in non-ambulatory children and adolescents with CP.}, added-at = {2014-07-19T21:03:20.000+0200}, author = {Plotkin, Horacio and Coughlin, Susan and Kreikemeier, Rose and Heldt, Kathryn and Bruzoni, Matias and Lerner, Gary}, biburl = {https://www.bibsonomy.org/bibtex/26d83ab17c36728707d598e3c50953655/ar0berts}, doi = {10.1017/S0012162206001526}, groups = {public}, interhash = {2c1e149b3b34e9e30dcddac2b040a82b}, intrahash = {6d83ab17c36728707d598e3c50953655}, journal = {Dev Med Child Neurol}, keywords = {Adolescent; Bone Density; Density Conservation Agents; Diseases, Metabolic; Cerebral Palsy; Child; Child, Preschool; Diphosphonates; Disabled Children; Dose-Response Relationship, Drug; Female; Fractures, Bone; Humans; Infusions, Intravenous; Male; Mobility Limitation; Pilot Projects; Severity of Illness Index; Treatment Outcome}, month = Sep, number = 9, pages = {709--712}, pii = {S0012162206001526}, pmid = {16904014}, timestamp = {2014-07-19T21:03:20.000+0200}, title = {Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.}, url = {http://dx.doi.org/10.1017/S0012162206001526}, username = {ar0berts}, volume = 48, year = 2006 }